전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-4 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,016 programs
CGTLimited DatastaleiCell Gene TherapeuticsPhase 1

Anti-CD33 CAR T-cells (Anti-CD33 CAR T-cells)

Relapsed and/or Refractory Acute Myeloid Leukemia; High Risk Hematologic Malignancies · CD33

#CD33#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 12Status Active
CGTLimited DatastaleBiohaven Pharmaceuticals, Inc.Phase 1

CIML-NK cell therapy (CIML-NK cell therapy)

Acute Myeloid Leukemia Refractory; Acute Myeloid Leukemia, in Relapse · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 12Status Recruiting
CGTLimited DatastaleShenzhen Institute for Innovati…Phase 2

Drugs and anti-CD19 CAR transduced T cells (Drugs and anti-CD19 CAR transduced T cells)

Acute Lymphocytic Leukemia; Chronic Lymphocytic Leukemia · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 12Status Active
ADCStandard DatabasestaleRochePhase 2

Polatuzumab Vedotin, Rituximab, Lenalidomide (Polatuzumab Vedotin, Rituximab, Lenalidomide)

Diffuse Large B Cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#ADC#Phase2#antibody-drug-conjugate#Roche
Trials 12Status Recruiting
CGTCurated CorestaleREGENXBIO Inc.Phase 2

RGX-314 (RGX-314)

Neovascular Age-related Macular Degeneration; Wet Age-related Macular Degeneration · Neovascular Age-related Macular Degenera

#NeovascularAge-relatedMacularDeg#CGT#Phase2#BioJungboMoa-pick#cell-gene-therapy+4
Trials 12Status Active
AntibodyLimited DatastaleShi MingPhase 2

Candonilimab (Candonilimab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#Shi
Trials 11Status Discontinued
ADCStandard DatabasestaleAstraZenecaPhase 2

durvalumab (Imfinzi, Datopotamab deruxtecan + Durvalumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastNeoplasms+2
Trials 11Status Recruiting
CGTLimited DatastaleKyverna TherapeuticsPhase 2

KYV-101 anti-CD19 CAR-T cell therapy (KYV-101 anti-CD19 CAR-T cell therapy)

Lupus Nephritis; Lupus Nephritis - WHO Class III · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 11Status Discontinued
AntibodyLimited DatastaleAmgenPhase 2

Panitumumab-IRDye800 (Panitumumab-IRDye800)

Pancreatic Adenocarcinoma · Malignant Brain Neoplasm

#MalignantBrainNeoplasm#Antibody#Phase2#monoclonal-antibody#PancreaticAdenocarcinoma+1
Trials 11Status Recruiting
AntibodyLimited DatastaleJanssenPhase 1

Topical infliximab (Topical infliximab)

Sterile Corneal Melt · Glaucoma Following Surgery

#GlaucomaFollowingSurgery#Antibody#Phase1#monoclonal-antibody#SterileCornealMelt+1
Trials 11Status Active
CGTLimited DatastaleCARsgen Therapeutics Co., Ltd.Phase 1

anti-GPC3 CAR-T (anti-GPC3 CAR-T)

Advanced Hepatocellular Carcinoma · Advanced Hepatocellular Carcinoma

#AdvancedHepatocellularCarcinoma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 11Status Recruiting
AntibodyLimited DatastaleGenentech, Inc.Phase 3

Cevostamab (Cevostamab)

Relapsed or Refractory Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#monoclonal-antibody#RelapsedorRefractoryMultipleMyel+1
Trials 10Status Recruiting
CGTLimited DatastaleShenzhen Celconta Life Science …Phase 1

Claudin18.2-targeted CAR-T Cells (Claudin18.2-targeted CAR-T Cells)

Colorectal Neoplasia · Colorectal Neoplasia

#ColorectalNeoplasia#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 10Status Recruiting
CGTLimited DatastaleChongqing University Cancer Hos…Phase 2

Oncolytic Virus H101 (Oncolytic Virus H101)

Rectal Neoplasms; Rectal Adenocarcinoma · Rectal Neoplasms

#RectalNeoplasms#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 10Status Recruiting
ADCStandard DatabasestaleMerck Sharp & Dohme LLCPhase 2

Zilovertamab vedotin (Zilovertamab vedotin)

Lymphoma, Large B-Cell, Diffuse · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#Lymphoma+3
Trials 10Status Active
CGTLimited DatastaleNovartisPhase 1

huCART19 (huCART19)

Acute Lymphocytic Leukemia; Diffuse Large Cell Lymphoma · Acute Lymphoblastic Leukemia

#AcuteLymphoblasticLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 10Status Active
CGTLimited DatastaleUniversity of PennsylvaniaPhase 1

huCART19 Cells (huCART19 Cells)

Chemotherapy Resistant Acute Lymphoblastic Leukemia; Refractory Acute Lymphoblastic Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 10Status Recruiting
CGTLimited DatastaleMiltenyi Biomedicine GmbHPhase 2

MB-CART2019.1 (zamtocabtagene autoleucel, zamtocabtagene autoleucel (MB-CART2019.1))

Refractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed Diffuse Large B Cell Lymphoma · B-Cell Neoplasm

#B-CellNeoplasm#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 10Status Recruiting
CGTLimited DatastalePeproMene Bio, Inc.Phase 1

BAFFR-CAR T cells (BAFFR-CAR T cells)

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 9Status Recruiting
ADCStandard DatabasestaleGSKPhase 2

belantamab mafodotin (Blenrep, GSK2857916, Belantamab Mafodotin-Blmf)

Multiple Myeloma; Neoplasms · Multiple Myeloma

#MultipleMyeloma#ADC#Phase2#antibody-drug-conjugate#Neoplasms+1
Trials 9Status Recruiting

11 / 51 pages

← PreviousNext →